The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Merced County officials have warned residents of a counterfeit letter claiming to be from the county’s Department of Public ...

If you have AIDS, you will have HIV, but not everyone with HIV will develop AIDS, this is thanks to the many treatment ...

Like its English-language predecessor, which launched in 2016, this Spanish-language patient community from MyHealthTeam is ...